Annovis Bio (FRA:07X) EBITDA Margin %: 0.00% (As of Mar. 2026)


FRA:07X Annovis Bio Inc FRA:07X
32 GF Score
Price €1.52
! 1 Warning Sign
View Full Analysis

What is Annovis Bio EBITDA Margin %?

Annovis Bio FRA:07X +0.40% 32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Annovis Bio ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Annovis Bio's EBITDA for the three months ended in Mar. 2026 was €-15.58 Mil. Annovis Bio's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Annovis Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Annovis Bio  (FRA:07X) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Annovis Bio EBITDA Margin % Related Terms

Annovis Bio EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Annovis Bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio EBITDA Margin % Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Annovis Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:07X vs CSBR, HYFT, GANX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Annovis Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annovis Bio EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Annovis Bio's EBITDA Margin % falls into.


FRA:07X
32GF Score
Annovis Bio Inc FRA:07X
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Annovis Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-25.36/0
= %

Annovis Bio's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.58/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Annovis Bio (FRA:07X) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Annovis Bio and its competitors. According to the industry distribution chart, Annovis Bio ranks #999999 out of 945 companies in the Biotechnology industry.
Is Annovis Bio's EBITDA Margin % too high?
Annovis Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Annovis Bio ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's EBITDA Margin % compare to CSBR and HYFT?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #999999 out of 945 companies for EBITDA Margin %. This places Annovis Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Annovis Bio and its competitors. Annovis Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score

Get the complete analysis for FRA:07X

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.52
Price